Literature DB >> 11455468

Radiotherapy as a component of multidisciplinary treatment of bile duct cancer: a surgeon's perspective.

T Todoroki1.   

Abstract

Surgery is the only curative treatment for bile duct cancer (BDC). However, because of frequent loco-regional recurrence, radical surgery during advanced stages of the disease is often unsuccessful. Despite recent evidence of improvement in patient survival and quality of life, alternatives such as radiation therapy have not been fully developed and remain controversial. This article reviews current publications that deal with various irradiation procedures for the treatment of BDC, with particular attention to adjuvants to surgical resection, including liver transplantation, as a component of treatment of BDC. Specialized boost techniques, including conformal external beam irradiation (EBRT), brachytherapy via transhepatic catheters or a retrograde endoscopic stent, or intraoperative irradiation with electrons (IOERT), are summarized in relation to patient survival.

Entities:  

Mesh:

Year:  2001        PMID: 11455468     DOI: 10.1007/s005340170035

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  3 in total

1.  Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis.

Authors:  Clifton D Fuller; Samuel J Wang; Mehee Choi; Brian G Czito; John Cornell; Tania M Welzel; Katherine A McGlynn; Join Y Luh; Charles R Thomas
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

2.  The role of liver transplantation in the treatment of hilar cholangiocarcinoma.

Authors:  Hauke Lang; Georgios C Sotiropoulos; Gernot M Kaiser; Ernesto P Molmenti; Massimo Malagó; Christoph E Broelsch
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

3.  A salvage treatment for solid liver metastasis after radical resection of Klatskin tumour.

Authors:  Yuji Nakagawa; Takeshi Todoroki; Tadashi Kondo; Toru Kawamoto; Nobuhiro Ohkohchi; Kiyoshi Ohara
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.